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ANSWER
This is a folliculocystic and collagen hamartoma
(FCCH), a rare benign collagen hamartoma strongly associ-
ated with tuberous sclerosis complex (TSC). Hamartomas in
TSC with mutations in the TSC1 (encodes for hamartin) and
TSC2 (tuberin) genes have high mTORC1 activity as a result
of lack of inhibition by this TSC tumor suppressor complex.
High mTORC1 activity stimulates proliferation of fibroblasts,
keratinocytes, hair follicles, and sebaceous glands.1 However,
for the development of hamartomas, a second somatic event is
required, in addition to the germline TSC1/TSC2 mutation.2
DISCUSSION
TSC is an autosomal dominant disorder caused by
mutations in the TSC1 (30%) or TSC2 (65%) gene.2 In 5%–
10% of TSC patients, no mutation can be identified, and some
patients have low-level mosaicism.2 For detailed information
about the diagnostic and genetic criteria, we refer to the Inter-
national Tuberous Sclerosis Complex Consensus conference,
held in 2012.
FCCH was suggested as a new type of complex
hamartoma related with TSC by Torrelo et al in 2012.3 They
described 6 male patients with congenital/early childhood
skin lesions consisting of large plaques with an irregular sur-
face that became scattered with numerous comedo-like open-
ings over time. Five of the 6 patients had a definite clinical
diagnosis of TSC. After this initial description, only 4 addi-
tional case reports have been published, including 3 female
patients1,4,5 and 1 patient without TSC.6
FCCH histopathologically resembles angiofibroma,
shagreen patches, and TSC-unrelated collagen nevi. These
lesions have in common that they show coarse, rather than
delicate, collagen fibers, which are often haphazardly ar-
ranged through the dermis. In contrast to the previously
mentioned lesion, FCCH shows collagen fibers that are
arranged in a concentric array around hair follicles. This
perifollicular fibrosis is often associated with some distortion
of the pilosebaceous units. Furthermore, infundibular cyst
formation is a characteristic feature, which can only be
observed in FCCH.6 Clinically, the case might also resemble
plexiform neurofibroma (in NF1) or nevus sebaceous. In
nevus sebaceous, the appearance of sebaceous gland hyper-
plasia with or without immature hair follicles in the dermis is
the key feature. This is in contrast to the mature hair follicles
surrounded by fibrosis and inflammation as can be seen in
FCCH. Finally, fibrous hamartoma of infancy is a rare soft-
tissue lesion that may enter the differential diagnosis. This
lesion harbors a characteristic triphasic morphology of fat,
mesenchymal tissue, and fibroblastic fascicles.4
The final diagnosis of FCCH requires familiarity with
the clinical features and the 3 histopathological features of
this lesion. Likely, FCCH is underrecognized because not
many clinicians and pathologist are familiar with this
relatively new entity. When FCCH is the presenting feature
of TSC, early recognition is important for further clinical
workup leading to a final diagnosis. In patients already
diagnosed with TSC, early recognition of this benign entity
within the spectrum of TSC could prevent distress and
anxiety during the diagnostic process. Altogether, we think
it is important to recognize this rare, relatively new entity and
to further study its relation to TSC.
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